The Food and Drug Administration has approved a new weight loss medication that produces average weight reductions of 22 percent, surpassing the results of all previously approved pharmaceutical treatments. The drug, called Retatrutide Plus, combines the mechanisms of three existing obesity medications.
"This is a landmark approval that will transform how we treat obesity," said FDA Commissioner Dr. Robert Califf. "For patients who have struggled with weight loss through diet and exercise alone, this medication offers hope for meaningful, sustained improvement."
Clinical trials demonstrated that participants taking Retatrutide Plus lost an average of 22.4 percent of body weight over 72 weeks, compared to 15 percent for semaglutide alone and 12 percent for tirzepatide.
The medications will carry a boxed warning about potential thyroid C-cell tumors observed in rodent studies, though this risk has not been confirmed in humans. The FDA has required a REMS program to ensure prescribers and patients understand the risks.
"While these results are remarkable, long-term safety data and cardiovascular outcomes studies are still pending," said Dr. Caroline Apovian of Boston Medical Center. "We should reserve these medications for appropriate patients while we gather more evidence."